Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Flecainide, a therapeutic option in a patient with long QT syndrome type 3 caused by the heterozygous V411M mutation in the SCN5A gene.

Revista espanola de cardiologia (English ed.) - 1 Nov 2012

Carrasco José Ignacio, Izquierdo Isabel, Medina Pilar, Arnau Miguel Ángel, Salvador Antonio, Zorio Esther

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-Arrhythmia Agents
Share to Cardiac Conduction System Disease
Share to Electrocardiography

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Flecainide

Share to Heterozygote

Share to Infant

Share to Long QT Syndrome

Share to NAV1.5 Voltage-Gated Sodium Channel

Source

Identifiers

PMID: 22721569
DOI: 10.1016/j.recesp.2012.03.014

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Flecainide, a therapeutic option in a patient with long QT syndrome type 3 caused by the heterozygous V411M mutation in the SCN5A gene.PMID 22721569Read ↗

Multifocal Ectopic Purkinje-Related Premature Contractions Syndrome in R222Q-SCN5A Gene Mutation Carriers Treated With Flecainide.Semantic proximity Read ↗

Long-term flecainide therapy in type 3 long QT syndrome.Semantic proximity Read ↗

Antiarrhythmic Action of Flecainide in Polymorphic Ventricular Arrhythmias Caused by a Gain-of-Function Mutation in the Nav 1.5 Sodium Channel.Semantic proximity Read ↗

Effects of flecainide in patients with new SCN5A mutation: mutation-specific therapy for long-QT syndrome?Semantic proximity Read ↗

Flecainide for recurrent malignant ventricular arrhythmias in two siblings with Andersen-Tawil syndrome.Semantic proximity Read ↗

A mutation in the sodium channel is responsible for the association of long QT syndrome and familial atrial fibrillation.Semantic proximity Read ↗

[Use of Pharmacogenetic Information for Therapeutic Drug Monitoring of an Antiarrhythmic Drug].Semantic proximity Read ↗

The elusive link between LQT3 and Brugada syndrome: the role of flecainide challenge.Semantic proximity Read ↗

Channel openings are necessary but not sufficient for use-dependent block of cardiac Na(+) channels by flecainide: evidence from the analysis of disease-linked mutations.Semantic proximity Read ↗

Normalization of ventricular repolarization with flecainide in long QT syndrome patients with SCN5A:DeltaKPQ mutation.Semantic proximity Read ↗

Effect of the antimalarial drug halofantrine in the long QT syndrome due to a mutation of the cardiac sodium channel gene SCN5A.Semantic proximity Read ↗

Gating properties of SCN5A mutations and the response to mexiletine in long-QT syndrome type 3 patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.